Skip to main content
SpringerLink
Log in

The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Evidence suggests cannabidiol (CBD) displays broad therapeutic potential in the context of anxiety; however, no study has examined the effects of CBD on worry, a defining, cognitive feature of anxiety. Additionally, no study has examined the effects of an acute, single dose of CBD compared to repeated CBD administration.

Objectives

Within a sample of 63 individuals with elevated trait worry, the current study aimed to assess the effects of an empirically-derived high dose of CBD (i.e., 300mg) compared to a commercially-derived dose of CBD (i.e., 50mg) versus placebo on worry severity and anxiety symptoms after an acute dose and after a 2-week administration period.

Results

Results indicated no effect of acute CBD dosing on worry severity or anxiety symptoms. Repeated CBD administration similarly did not impact worry severity; however, 300mg of CBD reduced anxiety symptoms across the 2-week administration period compared to placebo.

Conclusions

Taken together, these findings suggest 300mg of oral CBD does not attenuate cognitive symptoms of anxiety (i.e., worry), following both acute and repeated administration. Some evidence for repeated administration of 300mg on physical symptoms of anxiety was obtained. Findings from the current study suggest CBD’s modest anxiolytic effects may be specific to the physical aspects of anxious arousal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Alonso-Pedrero, L., Bes-Rastrollo, M., & Marti, A. (2019). Effects of antidepressant and antipsychotic use on weight gain: a systematic review. In Obesity Reviews (Vol. 20, 12, pp. 1680–1690). Blackwell Publishing Ltd. https://doi.org/10.1111/obr.12934

    Chapter  Google Scholar 

  • Amrhein V, Trafimow D, Greenland S (2019) Inferential statistics as descriptive statistics: There is no replication crisis if we don’t expect replication. The American Statistician 73(sup1):262–270

    Article  Google Scholar 

  • Andrade LH, Alonso J, Mneimneh Z, Wells JE, Al-Hamzawi A, Borges G, Bromet E, Bruffaerts R, De Girolamo G, De Graaf R, Florescu S (2014) Barriers to mental health treatment: results from the WHO World Mental Health surveys. Psychol Med 44(6):1303–1317. https://doi.org/10.1017/S0033291713001943

    Article  CAS  PubMed  Google Scholar 

  • Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP (1998) Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess 10(2):176

    Article  Google Scholar 

  • Asmundson GJG, Paluszek MM, Landry CA, Rachor GS, McKay D, Taylor S (2020) Do pre-existing anxiety-related and mood disorders differentially impact COVID-19 stress responses and coping? J Anxiety Disord 74:102271. https://doi.org/10.1016/j.janxdis.2020.102271

    Article  PubMed  PubMed Central  Google Scholar 

  • Bangdiwala SI (2016) Understanding Significance and P-Values. Nepal J Epidemiol 6(1):522–524. https://doi.org/10.3126/nje.v6i1.14732

    Article  PubMed  PubMed Central  Google Scholar 

  • Barlow DH, Raffa SD, Cohen EM (2002) Psychosocial treatments for panic disorders, phobias, and generalized anxiety disorder. In: Nathan PE, Gorman JM (eds) A guide to treatments that work. Oxford University Press, pp 301–335

    Google Scholar 

  • Benedetti F, Carlino E, Piedimonte A (2016) Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 15(7):736–747

    Article  PubMed  Google Scholar 

  • Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, de Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JAS (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacol 36(6):1219–1226. https://doi.org/10.1038/npp.2011.6

    Article  CAS  Google Scholar 

  • Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, Jackson H, Hetrick S, Parker A, Spelman T, Kevin R, McGregor IS, McGorry P, Amminger GP (2022) Cannabidiol for treatment-resistant anxiety disorders in young people. J Clin Psychiatry 83(5). https://doi.org/10.4088/JCP.21m14130

  • Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825–836. https://doi.org/10.1007/s13311-015-0387-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW (2022) Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology 239(5):1499–1507

    Article  CAS  PubMed  Google Scholar 

  • Borkovec TD, Ray WJ, Stober J (1998) Worry: a cognitive phenomenon intimately linked to affective, physiological, and interpersonal behavioral processes. Cogn Ther Res 22(6):561–576. https://doi.org/10.1023/A:1018790003416

    Article  Google Scholar 

  • Brown TA, Antony MM, Barlow DH (1992) Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. Behav Res Ther 30(1):33–37

    Article  CAS  PubMed  Google Scholar 

  • Buffett-Jerrott SE, Stewart SH (2002) Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8(1):45–58

    Article  CAS  PubMed  Google Scholar 

  • Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond, B, Biol Sci 367(1607):3364–3378

    Article  CAS  PubMed  Google Scholar 

  • Charlotte's web™ CBD oil,2023 CBD Gummies and Cream Official Site. Charlotte’s Web™ CBD Oil, CBD Gummies and Cream Official Site. February 21, 2023, from https://www.charlottesweb.com/

  • Chye Y, Christensen E, Solowij N, Yücel M (2019) The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder. Front Psych 10:63

    Article  Google Scholar 

  • Crippa JAS, Nogueira Derenusson G, Borduqui Ferrari T, Wichert-Ana L, Duran FLS, Martin-Santos R, Vinícius Simões M, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JEC (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol 25(1):121–130. https://doi.org/10.1177/0269881110379283

    Article  CAS  PubMed  Google Scholar 

  • Crippa JAS, Zuardi AW, Guimarães FS, Campos AC, de Lima Osório F, Loureiro SR, dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA et al (2021) Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the covid-19 pandemic: Aa randomized clinical trial. JAMA Netw Open 4(8). https://doi.org/10.1001/jamanetworkopen.2021.20603

  • Fabris D, Carvalho MC, Brandão ML, Prado WA, Zuardi AW, Crippa JA, ..., Genaro K (2022) Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. J Psychopharmacol 36(12):1371–1383

  • Fatseas M, Serre F, Swendsen J, Auriacombe M (2018) Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: an ecological momentary assessment study. Drug Alcohol Depend 187:242–248. https://doi.org/10.1016/j.drugalcdep.2018.03.008

    Article  PubMed  Google Scholar 

  • Fergus TA, Valentiner DP, McGrath PB, Jencius S (2010) Shame- and guilt-proneness: Relationships with anxiety disorder symptoms in a clinical sample. J Anxiety Disord 24(8):811–815. https://doi.org/10.1016/j.janxdis.2010.06.002

    Article  PubMed  Google Scholar 

  • Feurer C, Francis J, Ajilore O, Craske MG, Phan KL, Klumpp H (2021) Emotion regulation and repetitive negative thinking before and after CBT and SSRI treatment of internalizing psychopathologies. Cogn Ther Res 45:1064–1076

    Article  Google Scholar 

  • Fiksdal A, Hanlin L, Kuras Y, Gianferante D, Chen X, Thoma MV, Rohleder N (2019) Associations between symptoms of depression and anxiety and cortisol responses to and recovery from acute stress. Psychoneuroendocrinol 102:44–52. https://doi.org/10.1016/j.psyneuen.2018.11.035

    Article  CAS  Google Scholar 

  • Galaj E, Bi GH, Yang HJ, Xi ZX (2020) Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms. Neuropharmacology 167:107740. https://doi.org/10.1016/j.neuropharm.2019.107740

    Article  CAS  PubMed  Google Scholar 

  • Gillis MM, Haaga DA, Ford GT (1995) Normative values for the beck anxiety inventory, fear questionnaire, Penn state worry questionnaire, and social phobia and anxiety inventory. Psychol Assess 7(4):450

    Article  Google Scholar 

  • Gladstone GL, Parker GB, Mitchell PB, Malhi GS, Wilhelm KA, Austin MP (2005) A Brief Measure of Worry Severity (BMWS): personality and clinical correlates of severe worriers. J Anxiety Disord 19(8):877–892. https://doi.org/10.1016/j.janxdis.2004.11.003

    Article  PubMed  Google Scholar 

  • Gournay, L. (2022a). An experimental test of the effects of acute vs repeated cannabidiol administration on worry among high trait worriers: a double-blind, randomized placebo controlled trial. Retrieved from osf.io/uavrb

  • Gournay, L. (2022b). The effects of cannabidiol on anxiety among high trait worriers: a double-blind, randomized placebo controlled trial. Retrieved from osf.io/kmj8w

  • Hill AJ, Williams CM, Whalley BJ, Stephens GJ (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 133(1):79–97

    Article  CAS  PubMed  Google Scholar 

  • Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, Das RK, Lawn W, Morgan CJA, Curran HV (2018) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 113(9):1696–1705. https://doi.org/10.1111/add.14243

    Article  PubMed  PubMed Central  Google Scholar 

  • Jacobson NC, Newman MG (2017) Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. Psychol Bull 143(11):1155

    Article  PubMed  Google Scholar 

  • Johnson, H. M. (2019). Anxiety and Hypertension: Is there a link? a literature review of the comorbidity relationship between anxiety and hypertension. In Current Hypertension Reports (Vol. 21, Issue 9). Current Medicine Group LLC 1. https://doi.org/10.1007/s11906-019-0972-5

    Chapter  Google Scholar 

  • Katz N (2021) Design and conduct of confirmatory chronic pain clinical trials. Pain Rep 6(1)

  • Kim H-Y (2013) Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restor Dent Endod 38(1):52. https://doi.org/10.5395/rde.2013.38.1.52

    Article  PubMed  PubMed Central  Google Scholar 

  • Konnopka, A., & König, H. (2020). Economic burden of anxiety disorders: a systematic review and meta-analysis. In PharmacoEconomics (Vol. 38, Issue 1, pp. 25–37). Adis. https://doi.org/10.1007/s40273-019-00849-7

    Chapter  Google Scholar 

  • Kwee CM, van Gerven JM, Bongaerts FL et al (2022) Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool. J Psychopharmacol 36(12):1299–1314. https://doi.org/10.1177/02698811221124792

    Article  PubMed  PubMed Central  Google Scholar 

  • Lanier R, Erpelding N, Treister R, Lawal D, Mohanty M, Edler H, Katz N (2017) (468) Interventions to reduce the placebo response in clinical trials: a review of the literature. J Pain 18(4):S90

    Article  Google Scholar 

  • Ledoux J (2015) Anxious: Using the brain to understand and treat fear and anxiety. Penguin Random House Publishing

    Google Scholar 

  • Leen-Feldner EW, Bynion TM, Eglit GML, Bonn-Miller MO, Gournay LR, Feldner MT (2022) A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge. Psychopharmacology. https://doi.org/10.1007/s00213-022-06258-7

  • Leen-Feldner EW, Bynion TM, Gournay R, Bonn-Miller MO, Feldner MT (2021) Practical considerations for testing the effects of cannabidiol on human anxiety. J Anxiety Disord 82:102429. https://doi.org/10.1016/j.janxdis.2021.102429

    Article  PubMed  Google Scholar 

  • Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Rev Bras Psiquiatr 41(1):9–14. https://doi.org/10.1590/1516-4446-2017-0015

    Article  PubMed  Google Scholar 

  • Llera SJ, Newman MG (2020) Worry impairs the problem-solving process: results from an experimental study. Behav Res Ther 135:103759. https://doi.org/10.1016/j.brat.2020.103759

    Article  PubMed  PubMed Central  Google Scholar 

  • Loerinc AG, Meuret AE, Twohig MP, Rosenfield D, Bluett EJ, Craske MG (2015) Response rates for CBT for anxiety disorders: need for standardized criteria. Clin Psychol Rev 42:72–82

    Article  PubMed  Google Scholar 

  • Lucki I, Riekels K, Geller AM (1986) Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology:426–433

  • Masataka N (2019) Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol 10:2466. https://doi.org/10.3389/fpsyg.2019.02466

    Article  PubMed  PubMed Central  Google Scholar 

  • McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172(3):737–753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meyer TJ, Miller ML, Metzger RL, Borkovec TD (1990) Development and validation of the Penn state worry questionnaire. Behav Res Ther 28(6):487–495

    Article  CAS  PubMed  Google Scholar 

  • Millar SA, Stone NL, Yates AS, O’Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365. https://doi.org/10.3389/fphar.2018.01365

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mogg K, Baldwin DS, Brodrick P, Bradley BP (2004) Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacol 176:466–470

    Article  CAS  Google Scholar 

  • Mojtabai R, Olfson M, Sampson NA, Jin R, Druss B, Wang PS, Wells KB, Pincus HA, Kessler RC (2011) Barriers to mental health treatment: results from the National Comorbidity Survey Replication. Psychol Med 41(8):1751–1761. https://doi.org/10.1017/S0033291710002291

    Article  CAS  PubMed  Google Scholar 

  • Nanthakumar, S., Bucks, R. S., Skinner, T. C., Starkstein, S., Hillman, D., James, A., & Hunter, M. (2017). Assessment of the Depression, Anxiety, and Stress Scale (DASS-21) in Untreated Obstructive Sleep Apnea (OSA).

    Book  Google Scholar 

  • Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J (2021) Role of cannabidiol in the therapeutic intervention for substance use disorders. In: Frontiers in Pharmacology, vol 12. Frontiers Media S.A. https://doi.org/10.3389/fphar.2021.626010]

    Chapter  Google Scholar 

  • Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacol 10(2):181–191

    Article  CAS  Google Scholar 

  • Olatunji BO, Ebesutani C, David B, Fan Q, McGrath PB (2011) Disgust proneness and obsessive-compulsive symptoms in a clinical sample: structural differentiation from negative affect. J Anxiety Disord 25(7):932–938. https://doi.org/10.1016/j.janxdis.2011.05.006

    Article  PubMed  Google Scholar 

  • Pozzar R, Hammer MJ, Underhill-Blazey M, Wright AA, Tulsky JA, Hong F, Gundersen DA, Berry DL (2020) Threats of bots and other bad actors to data quality following research participant recruitment through social media: cross-sectional questionnaire. J Med Internet Res 22(10):e23021. https://doi.org/10.2196/23021

    Article  PubMed  PubMed Central  Google Scholar 

  • R Core Team (2022) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria https://www.R-project.org/

    Google Scholar 

  • Rutherford A (2009) Beyond the Box: BF Skinner’s technology of behaviour from laboratory to life, 1950s-1970s. University of Toronto Press

    Book  Google Scholar 

  • Sales AJ, Crestani CC, Guimarães FS, Joca SRL (2018) Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Prog Neuro-Psychopharmacol Biol Psychiatry 86:255–261. https://doi.org/10.1016/j.pnpbp.2018.06.002

    Article  CAS  Google Scholar 

  • Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, Abbafati C, Adolph C, Amlag JO, Aravkin AY, Bang-Jensen BL, Bertolacci GJ, Bloom SS, Castellano R, Castro E, Chakrabarti S, Chattopadhyay J, Cogen RM, Collins JK et al (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398(10312):1700–1712. https://doi.org/10.1016/S0140-6736(21)02143-7

    Article  Google Scholar 

  • Schulz K, Grimes D (2002) Unequal group sizes in randomized trials: guarding against guessing. Lancet 359:966–970

    Article  PubMed  Google Scholar 

  • Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, ..., Vandrey R (2020) Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend 211, p 107937

  • Spinella TC, Stewart SH, Naugler J, Yakovenko I, Barrett SP (2021) Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology 238:1965–1977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Startup HM, Erickson TM (2006) The penn state worry questionnaire (PSWQ). In: Worry and its psychological disorders: theory, assessment and treatment, pp 101–119

    Google Scholar 

  • Steiner AR, Petkus AJ, Nguyen H, Wetherell JL (2013) Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder. J Anxiety Disord 27(6):592–597

    Article  PubMed  Google Scholar 

  • Stoeber J, Bittencourt J (1998) Weekly assessment of worry: an adaptation of the Penn State Worry Questionnaire for monitoring changes during treatment. Behav Res Ther 36(6):645–656

    Article  Google Scholar 

  • Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013) A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol 69:825–834

    Article  CAS  PubMed  Google Scholar 

  • Terlizzi EP, Villarroel MA (2020) Symptoms of generalized anxiety disorder among adults: United States, 2019 (p. 8). US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics

    Google Scholar 

  • Turner, S., Mota, N., Bolton, J., & Sareen, J. (2018). Self-medication with alcohol or drugs for mood and anxiety disorders: a narrative review of the epidemiological literature. In Depression and Anxiety (Vol. 35, Issue 9, pp. 851–860). Blackwell Publishing Inc. https://doi.org/10.1002/da.22771

    Chapter  Google Scholar 

  • Viana AG, Gratz KL (2012) The role of anxiety sensitivity, behavioral inhibition, and cognitive biases in anxiety symptoms: structural equation modeling of direct and indirect pathways. J Clin Psychol 68(10):1122–1141. https://doi.org/10.1002/jclp.21890

    Article  PubMed  Google Scholar 

  • Viana AG, Stevens EN (2013) Interpersonal difficulties as an underlying mechanism in the anxiety-depression association. Behav Chang 30(4):273–282. https://doi.org/10.1017/bec.2013.26

    Article  Google Scholar 

  • West, S. G., Finch, J. F., & Curran, P. J. (1995). Structural equation models with nonnormal variables: Problems and remedies.

    Google Scholar 

  • Wilson JM, Lee J, Shook NJ (2021) COVID-19 worries and mental health: the moderating effect of age. Aging Ment Health 25(7):1289–1296

    Article  PubMed  Google Scholar 

  • Zinbarg RE (1998) Concordance and synchrony in measures of anxiety and panic reconsidered: a hierarchical model of anxiety and panic. Behav Ther 29(2):301–323. https://doi.org/10.1016/S0005-7894(98)80009-9

    Article  Google Scholar 

  • Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1_suppl):82–88

    Article  CAS  PubMed  Google Scholar 

  • Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa JAS (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8. https://doi.org/10.3389/fphar.2017.00259

Download references

Acknowledgements

Thank you to Dr. Huda Sheraf for serving as the onsite medical consultant. Additional thanks to undergraduate research assistants: Sydney Woychesin, Logan Denmon, Ashley Miller, Danielle Fernandez, Isabelle Escobar, Kathryn Niestoeckle, and Zoey Lewis.

Author information

Authors and Affiliations

  1. University of Arkansas, 216 Memorial Hall, Fayetteville, AR, 72701, USA

    L. Riley Gournay, Morgan L. Ferretti, Emily Vance, Anna Marie Nguyen, Eric Mann, Parker Williams & Ellen W. Leen-Feldner

  2. University of Mississippi, Oxford, USA

    Sarah Bilsky

  3. Laureate Institute for Brain Research, Tulsa, USA

    Eric Mann

Authors
  1. L. Riley Gournay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan L. Ferretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Bilsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily Vance
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Marie Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Parker Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ellen W. Leen-Feldner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Riley Gournay.

Ethics declarations

Conflict of interest

The first author (L. Riley Gournay) was the principal investigator of this study and recipient of study funding from Canopy Growth Corporation. At the time data were collected for the study, the last author’s (Ellen Leen-Feldner) partner (Matthew Feldner) was employed by Canopy Growth Corporation. A conflict of interest management plan was established prior to study commencement and adhered to across the duration of the study. Notably, neither Dr. Feldner nor Canopy Growth Corporation played any role in the study design, execution, analysis, or dissemination of findings.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gournay, L.R., Ferretti, M.L., Bilsky, S. et al. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial. Psychopharmacology 240, 2147–2161 (2023). https://doi.org/10.1007/s00213-023-06437-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-023-06437-0

Keywords

Search

Navigation